Research programme: protein A mimetics - ProMetic Life Sciences

Drug Profile

Research programme: protein A mimetics - ProMetic Life Sciences

Alternative Names: Mimetic A; PBI-0032; PBI-1308

Latest Information Update: 23 Jun 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ProMetic Life Sciences
  • Developer Laboratorios Dermatologicos Darier; ProMetic Life Sciences
  • Class Triazines
  • Mechanism of Action Fc receptor antagonists; Immunomodulators; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Atopic dermatitis; Autoimmune disorders; Glomerulonephritis; Prostate cancer; Psoriasis

Most Recent Events

  • 31 May 2014 Preclinical trials in Glomerulonephritis in Canada (PO)
  • 04 Apr 2011 Preclinical development of PBI 1308 is ongoing in Canada
  • 16 Apr 2008 Preclinical trials in Prostate cancer in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top